Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2024-09-17 Board/Management Inform…
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BIOS_PR_Ve´ronique Pomi_EN_Final.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing the resignation of a senior executive, Véronique Pomi-Schneiter, as Deputy CEO. This type of announcement, detailing changes in the company's board of directors or senior management, directly corresponds to the definition of Board/Management Information (MANG). The text includes a date, company name, the specific personnel change, and quotes from the CEO regarding the transition.
2024-09-17 English
BIOS_PR_Ve´ronique Pomi_FR_Final.pdf
Board/Management Information Classification · 100% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE – INFORMATION PRIVILÉGIÉE" (Press Release – Privileged Information) and announces the resignation of a key executive, Véronique Pomi-Schneiter, from her role as Deputy CEO. This type of announcement regarding changes in senior management directly corresponds to the definition of Board/Management Information (MANG). It is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2024-09-17 French
BIOS_PR_2024_08_16- Notification_ABO_EN_FINAL.pdf
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled as a "Transparency notification received from ABO Infinium Americas OpCo LTD." and details the crossing of a major shareholding threshold (5%) as per Article 14 of the relevant law. It specifies the person subject to notification, the transaction date, and the resulting change in voting rights. This content directly corresponds to the definition of a Major Shareholding Notification, which is classified under the code MRQ.
2024-08-19 English
BIOS_PR_2024_08_16-Notification_ABO_FR_FINAL.pdf
Major Shareholding Notification Classification · 98% confidence The document is titled "COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE" (Press Release - Regulated Information) and announces the receipt of a transparency notification regarding a change in significant shareholding (crossing the 5% threshold) by ABO Infinium Americas OpCo LTD. This type of filing, which reports changes in major share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is presented as a press release, the core content is the notification of a significant ownership change, not just an announcement of a report (RPA) or a general regulatory filing (RNS). The document explicitly details the threshold crossed, the date, and the chain of control, confirming it is the substance of a major shareholding disclosure.
2024-08-19 French
BIOS EPO MS Patent August 2024 _EN_FINAL.pdf
Legal Proceedings Report Classification · 99% confidence The document is explicitly labeled as a "PRESS RELEASE – INSIDE INFORMATION" and announces a significant corporate development: the European Patent Office (EPO) granting a key patent to Medsenic regarding the use of arsenic trioxide for treating multiple sclerosis. This type of announcement, detailing a specific, material, non-financial event (like a patent grant or clinical trial update) released to the public via a press release, fits best under the general category of regulatory or material event disclosure. Since it is not a full financial report (10-K, IR), a specific management change (MANG), a dividend notice (DIV), or a formal voting result (DVA), the most appropriate classification is the general regulatory filing/announcement category, RNS, as it serves as a material disclosure to the market.
2024-08-14 English
BIOS EPO MS Patent August 2024 _FR_FINAL.pdf
Regulatory Filings Classification · 100% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIEE" (Press Release – Privileged Information) and is dated 14/08/2024. It announces a specific corporate event: the European Patent Office (OEB) intending to grant a key European patent to Medsenic (a subsidiary of BioSenic) regarding the use of arsenic trioxide for treating multiple sclerosis. This type of announcement, detailing a significant development like patent grant or clinical trial progress, is typically classified as an Earnings Release (ER) if it contains key financial highlights, or a Regulatory Filing (RNS) if it's a general announcement. However, since this is a formal press release detailing a major operational/IP development, and it is not a full financial report (10-K, IR), a management discussion (MDA), or a specific transaction notice (CAP, TAR), it fits best under the general category for significant corporate news announcements. Given the options, 'Earnings Release' (ER) is often used broadly for material news releases, but 'Regulatory Filings' (RNS) serves as the best fallback for significant, non-standard announcements. Since this is a press release announcing a patent grant, which is material information, and it doesn't fit the specific definitions for ER (which usually focuses on financial results), I will classify it as a general Regulatory Filing (RNS) as it is a formal, privileged communication to the market about a key development, or potentially an Earnings Release if interpreted broadly as material news. Given the focus on IP and clinical development rather than quarterly results, RNS is safer, but ER is often used for press releases. Let's re-evaluate based on the definitions. It is not an ER (which focuses on financial results). It is not a CAP, TAR, or DIV. It is a formal announcement of a significant event (patent grant). This falls under the scope of general regulatory announcements or privileged information dissemination. I will select RNS as the most appropriate general regulatory announcement category for significant, non-standard corporate news.
2024-08-14 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.